News
Events
TFDA Approves Shiner's Phenbuty phase 4 clinical trial protocol.
Events
Epistatus 10 mg oromucosal solution receives TFDA approval of the specific medicinal products' importing as a special case.
Events
Shiner's Permethrin 5% w/w Cream receives TFDA approval of the specific medicinal products' manufacturing as a special case.
Events
TFDA gives green light to clinical trial protocol for Shiner's new drug.
Events
Shiner has inked a deal with a Swiss company for a spray-type medication targeting chemotherapy-induced oral mucositis.
Events
Shiner announces our inclusion in the reference list of biopharmaceutical industry research and development service companies.
Events
Shiner is entrusted with the development of a NCE for a tumor-related project.
Events
Shiner enters into an exclusive supply and distribution agreement with a Dutch company for Class I medical products in the field of dermatology.
Events
Shiner signed an exclusive supply and distribution contract with a European company for orphan drugs.
Events